By Tom Zanki ( April 3, 2015, 3:11 PM EDT) -- Venture capital-backed Collegium Pharmaceutical Inc., a biotech developing a portfolio of abuse-deterrent drugs to treat chronic pain, on Thursday filed for an initial public offering that would raise $86.3 million, largely to fund its lead product candidate that the company hopes will challenge market-leading painkiller OxyContin....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.